A study testing whether a GLP-1 medicine, semaglutide, can help people lose weight.

Who can join: Adults 40 to 55, have obesity or are overweight, BMI 30+.
What you take: Semaglutide, given as part of the study. Check ClinicalTrials.gov for this trial's study groups, including any placebo or comparison medicine.
How long it lasts: The study runs about 4 months.
What you get: Costs vary by study. Ask the study team what this one covers, including the study medicine, visits and travel, before you sign the consent form.

This one may not fit you. We check your age, where you live, and the rules each study sets, then show the clinical trials that do.

Check my fit →

Phase Phase 4Sponsor William Marsh Rice UniversityDrug semaglutideClass GLP-1 RASites 1 USEnrollment target 20

What this study is for

Primary condition: GLP - 1. Also studied in: Obesity & Overweight, Muscle Loss, Exercise Intervention, Dietary Assessment.

Full scientific study title: Combatting Muscle Loss in Obese Adult Patients on GLP-1 Medications Through Dietary Counseling and Exercise During Treatment Evaluates Wheth.

Who can join

Age40 to 55SexAnyBMI30 or higher

Adults 40 to 55, have obesity or are overweight, BMI 30+. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.

Full medical eligibility (for you and your doctor)verbatim from the registry

This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.

Key inclusion criteria

Age between 40 and 55 years
Body Mass Index (BMI) greater than 30
Body fat percentage greater than 30% for males and 40% for females
Android to gynoid fat ratio greater than 1.0
Currently eligible for GLP-1 therapy

Key exclusion criteria

Presence of abnormal ECG findings, including arrhythmias or ischemic changes
Hypertensive response to exercise, defined as systolic blood pressure exceeding 250 mmHg or diastolic pressure exceeding 115 mmHg
Hypotensive response to exercise, defined as a drop in systolic pressure greater than 10 mmHg with increasing workload
VO₂ max below 15 ml/kg/min
Borg Rating of Perceived Exertion (RPE) greater than 19 during submaximal workloads

Where this trial runs

This trial has 1 sites across 1 state. Site contacts are listed for reference. They are not screening through this trial right now.

Texas1 site

Rice University
Houston, Texas

Follow this trial

We email you if NCT07554417 changes status, adds new sites in your state, or if a similar trial opens for the same condition.

Timeline

Scheduled start: April 6, 2026. Expected completion: August 6, 2026. Last updated on ClinicalTrials.gov: April 28, 2026.

Official source

Every Monday we check this trial against ClinicalTrials.gov, the federal registry for clinical research. Last checked September 4, 2026. Confirm the current status there before you contact a site:

View on ClinicalTrials.gov →

Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.

John Samaras, Founder and EditorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas.
About this site LinkedIn Contact

Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.